VANCOUVER, BC, July 30, 2026
Total Flow Medical has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Total Flow Medical Femoral Arterial (TFA) Cannula, marking a significant regulatory milestone for the medical device company as it prepares to introduce the technology to cardiac surgery centers across the United States. The TFA Cannula is indicated for extracorporeal circulation during cardiopulmonary bypass procedures for up to six hours and incorporates a balloon at its distal tip that is designed to allow blood flow to the cannulated limb. The clearance represents an important step in Total Flow Medical’s commercial development and supports the company’s broader objective of addressing unmet clinical needs in extracorporeal circulation while integrating new technology into established cardiac surgery workflows.
TFA Cannula Targets Key Challenge in Cardiopulmonary Bypass
Femoral arterial cannulation is commonly used to establish extracorporeal circulation during cardiac surgery, enabling a patient’s blood to circulate outside the body while cardiopulmonary bypass is performed. However, maintaining adequate blood flow to the cannulated limb remains an important consideration for cardiac surgeons and perfusion teams. Total Flow Medical developed the TFA Cannula specifically with this clinical challenge in mind. The device incorporates a distal balloon feature designed to allow blood flow to the cannulated limb during cardiopulmonary bypass, while providing clinicians with an arterial cannulation option intended to integrate with existing surgical procedures. According to the cleared indication, the TFA Cannula can be used to cannulate vessels and connect with accessory extracorporeal equipment. It is intended for adult patients with a common femoral artery diameter of 7.5 millimeters or greater and is designed for use in the femoral position as an arterial delivery cannula during cardiopulmonary bypass procedures lasting up to six hours.
FDA Clearance Opens Path Toward U.S. Commercial Launch
The FDA 510(k) clearance marks the beginning of Total Flow Medical’s U.S. commercial journey for the TFA Cannula. Following the regulatory milestone, the company is preparing for a U.S. market release and plans to work with cardiac surgery centers to support early clinical adoption. Total Flow Medical said the device was developed through collaboration among cardiac surgeons, perfusionists and engineers, with the objective of rethinking aspects of extracorporeal circulation beginning with femoral arterial cannulation. The cannula is accompanied by an introducer intended to facilitate appropriate insertion and placement within the vessel. By designing the technology around established clinical workflows, Total Flow Medical aims to provide surgical teams with a device that can be incorporated into existing cardiopulmonary bypass practices while addressing the need to support blood flow to the cannulated extremity. The clearance also represents an important transition for the company from device development toward commercialization and broader clinical use in the United States.
Advertisement
Total Flow Medical Advances Extracorporeal Circulation Technology
Total Flow Medical is focused on developing medical technologies for extracorporeal circulation, an essential component of many cardiovascular surgical procedures. The company’s strategy centers on identifying unmet clinical needs and developing solutions that can fit within established healthcare workflows. With FDA clearance secured, the TFA Cannula becomes an important component of that strategy and provides Total Flow Medical with a regulatory foundation for its planned U.S. commercialization activities. The device’s combination of femoral arterial access, compatibility with extracorporeal circulation equipment and a distal balloon designed to support blood flow to the cannulated limb differentiates its approach to cardiopulmonary bypass cannulation. As hospitals and cardiac surgery programs continue to evaluate technologies designed to improve procedural workflows and support patient management, the availability of newly cleared extracorporeal circulation devices could expand the options available to surgeons and perfusion teams. Total Flow Medical plans to engage cardiac surgery centers as it introduces the TFA Cannula to the U.S. market and supports early adoption. The FDA 510(k) clearance represents a major regulatory and commercialization milestone for Total Flow Medical and positions the TFA Cannula as a new medical device option for femoral arterial cannulation during cardiopulmonary bypass.
Source: Total Flow Medical press release
